UnitedHealth profits surge on AI-driven cost cuts
UnitedHealth Group reported a 75% year-over-year surge in third-quarter 2026 profits, reaching $4.11 billion, even as revenue dipped slightly to $112.7 billion from $113.2 billion in the same period the prior year. The company’s earnings growth marks its strongest quarterly performance since 2025, driven by a strategic shift toward AI-driven operational improvements, tighter health plan management, and an increased emphasis on value-based care. Executives stated these measures will support sustainable expansion in 2027 and beyond.
Behind the earnings jump, operating earnings climbed to $2.8 billion, up from $1.8 billion, while the operating margin expanded to 3.3% from 2.1%. The company also lowered its medical care ratio—the percentage of premiums spent on patient services—to 88.4%, down from 89.9%, indicating better cost discipline. However, commercial medical expenses are rising faster than anticipated, fueled by No Surprises Act disputes, higher-intensity treatments, and escalating specialty drug costs.
UnitedHealth Chair and CEO Stephen Hemsley identified AI as the foundation of the company’s turnaround. Already, AI tools summarize patient charts for 40% of clinicians, slashing appeal processing times by 26 times. Medicare Advantage enrollment workflows now incorporate health history and local plan data, while prior authorization requests are projected to fall by 30% by year-end—including a two-thirds reduction for pediatric cases.
AI and Medicare Advantage Workflow Gains
UnitedHealthcare CEO Tim Noel outlined 2027 priorities, including growth in high-value health maintenance organization plans, chronic condition special needs plans, and dual-eligible special needs plans for Medicare-Medicaid enrollees. Access remains robust, with 94% of Medicare-eligible individuals set to have a UnitedHealthcare plan next year, and 90% able to select a zero-premium Medicare Advantage option. However, the company’s star ratings declined, with only 67% of its plans earning four or five stars in 2027, down from 81% the prior year.
Optum Health, UnitedHealth’s services division, generated $22.9 billion in revenue and $735 million in operating earnings, though revenue fell as it reduced exposure in value-based care markets where clinician networks were overburdened. CEO Patrick Conway highlighted gains in home health visits (up 10%) and behavioral health referrals (doubled), with co-located specialists achieving engagement rates above 90%. Optum Insight is accelerating AI investments to enhance clinician productivity, with Conway targeting meaningful progress in 2027 and faster growth in 2028.
Cost Pressures and Capital Strategy Adjustments
The earnings call addressed ongoing cost challenges. Medicaid margins are expected to hover near -1% this year, though state funding updates remain inconsistent. CFO Wayne DeVeydt reaffirmed the company’s capital allocation focus: reinvesting in care delivery, AI, and technology while preserving balance sheet strength. UnitedHealth raised its full-year adjusted earnings outlook to at least $20.50 per share, up from a prior range of $19.50–$20. Hemsley suggested the lower end of the company’s 13%–16% long-term growth target could serve as a baseline for 2027, though a complete 2027 forecast will be released later.
UnitedHealth’s AI deployments are transforming both clinical workflows and policy operations. The company’s AI tools now automate Medicare Advantage plan selections by matching individual health records with local network options, reducing patient decision time. The system also identifies high-risk members for proactive interventions, though Hemsley noted the technology remains in early stages for specialty care coordination. The 30% reduction in prior authorization requests will prioritize urgent care approvals, with pediatric cases seeing the steepest declines.
Commercial medical costs are climbing beyond UnitedHealth’s initial 11% forecast, with No Surprises Act disputes adding administrative strain. Tim Noel cited rising intensity of clinical services, including advanced cancer therapies and rare disease treatments, as a primary driver, though no specific treatments were named. Specialty drug spending is projected to grow at a double-digit rate, though the company has not disclosed plans to negotiate further rebates with manufacturers. Some states have delayed rate adjustments, forcing UnitedHealth to absorb higher costs in certain markets.
2027 Growth Outlook Hinges on Execution
The company’s capital strategy reflects these financial tensions. Wayne DeVeydt emphasized reinvesting in care delivery and AI while maintaining a strong balance sheet, though he did not specify how much of the $1.5 billion AI budget will shift from administrative savings to clinical applications. The raised full-year adjusted earnings outlook of at least $20.50 per share assumes cost pressures stabilize, though Hemsley warned that 2027 performance will depend on executing the prior authorization reforms and AI-driven efficiency gains. The lower end of UnitedHealth’s 13%–16% long-term growth target now appears achievable, but a full 2027 outlook will be provided before year-end, pending further data on commercial cost trends and Medicaid reimbursements.
